05 · Five talking points
Five talking points
Bookmarks need a Mind Club sign-in. How sign-in works
Five talking points across your briefs- A second pan-RAS drug, Erasca’s ERAS-0015, reports responses in pancreatic cancer, from a small Phase 1 with no control group. Claim
- Daraxonrasib plus chemotherapy reached a 60.7% response rate first line in 61 patients; the randomized test is still to come. Claim
- Actinogen’s Xanamem missed its pivotal Alzheimer’s primary; the company now points to older patients. Claim
- An RNAi drug dosed four times a year is now approved for generalized myasthenia gravis, per Alnylam. Claim
- Sanofi’s reported interest in Insmed is a press report, not an announced deal. Analysis